Docetetaxel

Phase 2Small molecule

Merck & Co.

Docetetaxel is one of 78 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Carcinoma, Non-Small-Cell LungRecruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Carcinoma, Non-Small-Cell LungPhase 2

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

Lenvima

Eisai

Preclinical

6 4

Vizimpro

Pfizer

Preclinical

4 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 7

Docetetaxel

Merck & Co.

Phase 2

1 8

Remeron

OOrganon and Co

Preclinical

1 9

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06780085

Clinical

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung1 trial

KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06780085·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Docetetaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Docetetaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Docetetaxel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Docetetaxel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Carcinoma, Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News